Royce & Associates LP grew its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 2.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,599,700 shares of the medical instruments supplier’s stock after acquiring an additional 34,700 shares during the period. Royce & Associates LP owned 4.29% of Harvard Bioscience worth $8,398,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in HBIO. Engineers Gate Manager LP bought a new stake in shares of Harvard Bioscience during the 3rd quarter valued at $112,000. Alambic Investment Management L.P. bought a new stake in shares of Harvard Bioscience during the 3rd quarter valued at $138,000. Mackay Shields LLC bought a new stake in shares of Harvard Bioscience during the 2nd quarter valued at $160,000. Rhumbline Advisers bought a new stake in shares of Harvard Bioscience during the 2nd quarter valued at $164,000. Finally, Greenwood Capital Associates LLC bought a new stake in shares of Harvard Bioscience during the 3rd quarter valued at $287,000. Institutional investors and hedge funds own 74.27% of the company’s stock.
Shares of NASDAQ HBIO opened at $3.54 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.49 and a current ratio of 2.83. The firm has a market capitalization of $138.73 million, a price-to-earnings ratio of 31.00 and a beta of 1.30. Harvard Bioscience, Inc. has a 52-week low of $3.05 and a 52-week high of $6.70.
Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings results on Thursday, October 25th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.04. The company had revenue of $28.71 million for the quarter, compared to the consensus estimate of $28.50 million. Harvard Bioscience had a negative net margin of 4.18% and a positive return on equity of 5.54%. On average, equities analysts forecast that Harvard Bioscience, Inc. will post 0.12 earnings per share for the current year.
HBIO has been the topic of several recent analyst reports. ValuEngine downgraded shares of Harvard Bioscience from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 22nd. Zacks Investment Research downgraded shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Wednesday, September 26th.
ILLEGAL ACTIVITY WARNING: “Royce & Associates LP Acquires 34,700 Shares of Harvard Bioscience, Inc. (HBIO)” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/12/08/royce-associates-lp-acquires-34700-shares-of-harvard-bioscience-inc-hbio.html.
About Harvard Bioscience
Harvard Bioscience, Inc develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names.
Read More: Benefits of owning preferred stock
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.